Reported about 9 hours ago
Maxim Group has given AIM ImmunoTech Inc. (NYSEAMERICAN:AIM) a 'Buy' rating with a price target of $6.00, indicating a potential upside of 133%. The company's recent presentation at the 5th Annual Marie Sklodowska-Curie Symposium highlighted positive progress in their Ampligen clinical program for pancreatic cancer, reinforcing confidence in their treatment prospects. AIM ImmunoTech focuses on developing solutions for various cancers and viral diseases.
Source: YAHOO